{'Year': '2022', 'Month': 'Feb'}
UGT1A1 genotype-guided dosing of irinotecan: AÂ prospective safety and cost analysis in poor metaboliser patients.
To determine the safety, feasibility, pharmacokinetics, and cost of UGT1A1 genotype-guided dosing of irinotecan.